Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $44.7 million.

  • Haemonetics' Income from Continuing Operations rose 1932.58% to $44.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $175.4 million, marking a year-over-year increase of 3486.37%. This contributed to the annual value of $167.7 million for FY2025, which is 4262.83% up from last year.
  • Latest data reveals that Haemonetics reported Income from Continuing Operations of $44.7 million as of Q4 2025, which was up 1932.58% from $38.7 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Income from Continuing Operations ranged from a high of $58.0 million in Q1 2025 and a low of -$11.0 million during Q2 2021
  • Moreover, its 5-year median value for Income from Continuing Operations was $32.1 million (2022), whereas its average is $27.5 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 16261.2% in 2021, then surged by 54627.3% in 2022.
  • Haemonetics' Income from Continuing Operations (Quarter) stood at $14.8 million in 2021, then surged by 122.13% to $32.9 million in 2022, then fell by 5.15% to $31.2 million in 2023, then rose by 20.06% to $37.5 million in 2024, then increased by 19.33% to $44.7 million in 2025.
  • Its last three reported values are $44.7 million in Q4 2025, $38.7 million for Q3 2025, and $34.0 million during Q2 2025.